Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091417 | 0.87 | TP53 (0.55) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL28125379 | 0.83 | PSMB8 (0.54) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL28375846 | 0.82 | PSMB8 (0.52) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL31108949 | 0.82 | PSMB8 (0.52) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL19029197 | 0.82 | PSMB8 (0.52) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL5229918 | 0.81 | KDM4E (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27461697 | 0.81 | CYP2A6 (0.50) | CA12CA9KDM4EALDH1A1HPGD | |
| SCHEMBL6479111 | 0.81 | PSMB8 (0.51) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL6480210 | 0.81 | PSMB8 (0.51) | PSMB8CREBBPCA12CA1CA2 | |
| SCHEMBL6479909 | 0.81 | PSMB8 (0.51) | PSMB8CREBBPCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109475530-B | Aminoacyl indazole immunomodulators for treating autoimmune diseases | 洛克菲勒大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463341-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109475530-A | For treating the aminoacyl indazole immunomodulator of autoimmune disease | 洛克菲勒大学 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017205296-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205296-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI2, IL4I1, TFPI | PSMB8 1658/4885CREBBP 4074/4885CA12 3288/4885 |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | PSMB8 3498/4885CREBBP 528/4885CA12 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.